SCHEMBL6407121

SCHEMBL6407121

CC1C(C)C1(F)F

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23394524 1.00
SCHEMBL15591639 1.00
SCHEMBL7731926 0.87
SCHEMBL9907097 0.80
SCHEMBL13612915 0.77
Hydrochloric Acid SCHEMBL25302707 0.74
Hydrochloric Acid SCHEMBL25258352 0.74
SCHEMBL24908762 0.70
SCHEMBL11878621 0.70
SCHEMBL17675791 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023011608-A1 REGULATOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 上海枢境生物科技有限公司 2023-02-09 WO disclosed
US-20230002412-A1 INHIBITORS OF PEPTIDYLARGININE DEIMINASES GILEAD SCIENCES, INC. 2023-01-05 US disclosed
WO-2022150446-A1 TYK2 INHIBITORS BIOGEN MA INC. (US) 2022-07-14 WO disclosed
EP-3492464-A1 INTERMEDIATES FOR PREPARING INHIBITORS OF HEPATITIS C VIRUS Gilead Sciences, Inc. (US) 2019-06-05 EP disclosed
WO-2018093577-A1 CYCLOALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR AMGEN INC. (US) 2018-05-24 WO disclosed
US-20170290827-A1 INHIBITORS OF HEPATITIS C VIRUS GILEAD PHARMASSET LLC 2017-10-12 US disclosed
EP-3006444-B1 HETEROCYCLIC AMIDE COMPOUND NISSAN CHEMICAL IND LTD (JP) 2017-09-27 EP disclosed
US-9708314-B2 Heterocyclic amide compound NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2017-07-18 US disclosed
US-9708314-B2 Heterocyclic amide compound NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2017-07-18 US disclosed
US-9655944-B2 Inhibitors of hepatitis C virus GILEAD SCIENCES, INC. (US) 2017-05-23 US disclosed
WO-2008012180-A1 FUSED NAPHTHALENES MERCK PATENT GMBH (DE) 2008-01-31 WO disclosed
US-20050053552-A1 Phase shift colloids as ultrasound contrast agents QUAY STEVEN C (US) 2005-03-10 US disclosed
US-6569404-B1 Aqueous colloidal suspension, dispersed phase is gas microbubbles of perfluoropropane, perfluorobutane, perfluoropentane, perfluorohexane or sulfur hexafluoride; fluorinated amphiphile for stabilizing microbubbles AMERSHAM HEALTH A/S (NO) 2003-05-27 US disclosed
US-6245319-B1 Colloidal dispersions of perfluoropentane SONUS PHARMACEUTICALS, INC. 2001-06-12 US disclosed
EP-0680341-B1 PHASE SHIFT COLLOIDS AS ULTRASOUND CONTRAST AGENTS SONUS PHARMA INC (US) 2001-05-09 EP disclosed
EP-1038535-A2 Use of selected perfluorocarbons for the preparation of diagnostic ultrasound contrast agents SONUS PHARMACEUTICALS, INC. (US) 2000-09-27 EP disclosed
US-5876696-A Composition comprising a fluorine containing surfactant and perfluoropentane for ultrasound SONUS PHARMACEUTICALS, INC. (US) 1999-03-02 US disclosed
US-5558853-A WATER IMMISCIBLE FLUORINE COMPOUND SONUS PHARMACEUTICALS (US) 1996-09-24 US disclosed
EP-0680341-A1 PHASE SHIFT COLLOIDS AS ULTRASOUND CONTRAST AGENTS SONUS PHARMACEUTICALS, INC. (US) 1995-11-08 EP disclosed
WO-1994016739-A1 PHASE SHIFT COLLOIDS AS ULTRASOUND CONTRAST AGENTS SONUS PHARMACEUTICALS, INC. (US) 1994-08-04 WO disclosed